Relative potencies of various β-adrenoceptor antagonists (BAA) at the level of the human myocardial β-adrenoceptor-adenylate cyclase (AC) complex. Is intrinsic sympathomimetic activity (ISA) due to AC activation?

References

• Nutall A, Snow H M. The cardiovascular effects of ICI 118.587 a β1‐adrenoceptor partial agonist. Br J Pharmacol 1982; 77: 381
   PubMedGoogle Scholar
• Smith H J, Halliday S E, Earl D CN, Stribling D. Effects of selective (beta‐1 and beta‐2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141.292. J Pharmacol Exp Ther 1983; 226: 211–6
   PubMedGoogle Scholar
• Raeder E A, Verrier R L, Lown B. Intrinsic sympathomimetic activity and the effects of beta‐adrenergic blocking drugs on vulnerability to ventricular fibrillation. J Am Coll Cardiol 1983; 1(6)1442–6
   PubMedGoogle Scholar
• Kaumann A, Blinks J R. β‐adrenoceptor blocking agents as partial agonists in isolated heart muscle: dissociation of stimulated and blockade. Naunyn‐Schmiedebergs Arch Pathol 1980; 311: 237–48
   PubMedGoogle Scholar
• Clark B J, Menninger K, Bertholet A. Pindolol—the pharmacology of a partial agonist. Br J Clin Pharmacol 1982; 13(Suppl. 2)149–58
   Google Scholar
• Heikkilä J, Nieminen M S. Cardiac safety of acute beta blockade: intrinsic sympathomimetic activity is superior to beta‐1 selectivity. Am Heart J 1982; 104: 464–72
   PubMedGoogle Scholar
• Hombach V, Braun V, Hopp H ‐W, Gil‐Sanches D, Behrenbeck D W, Tauchert M, Hilger H H. Electrophysiological effects of cardioselective and non‐cardioselective β‐adrenoceptor blockers with and without ISA at rest and during exercise. Br J Clin Pharmacol 1982; 13(Suppl. 2)285–93
   Google Scholar
• Hansson L, Svensson A, Gudbrandsson T, Sivertsson R. Treatment of hypertension with β‐blockers with and without intrinsic sympathomimetic activity. J Cardiovasc Pharmacol 1983; 5(Suppl. 1)26–9
   Google Scholar
• Svendson T L. Central hemodynamics of β‐adrenoceptor blocking drugs: β1‐selectivity versus intrinsic sympathomimetic activity. J Cardiovasc Pharmacol 1983; 5(Suppl. 1)21–5
   Google Scholar
• Ariëns E J. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983; 5(Suppl. 1)8–15
   Google Scholar
• Clark B J. Beta‐adrenoceptor‐blocking agents: are pharmacologic differences relevant?. Am Heart J 1982; 104: 334–46
   PubMedGoogle Scholar
• Langer S Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981; 32: 337–62
   Web of Science ®Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Golf S, Jahnsen T, Attramadal H, FrØysaker T, Hansson V. Catecholamine responsive adenylate cyclase in human myocardial preparations. Scand J Clin Lab Invest 1984; 44: 317–27
   PubMed Web of Science ®Google Scholar
• Golf S, LØvstad R, Hansson V. β‐adrenoceptor density and relative number of β‐adrenoceptor subtypes in biopsies from human right atrial, left ventricular and right ventricular myocardium. Cardiovasc Res 1985; 19: 636–41
   PubMedGoogle Scholar
• Abramowitz J, Iyengar R, Birnbaumer L. Guanine nucleotide and magnesium ion regulation of the interaction of gonadotropic and β‐adrenergic receptors with their hormones: a comparative study using a single membrane system. Endocrinology 1982; 110: 336–46
   PubMedGoogle Scholar
• Golf S, Myhre E, Abdelnoor M, Andersen D, Hansson V. Hypertrophic cardiomyopathy (HOCM) characterized by β‐adrenoceptor density, relative amount of β‐adrenoceptor subtypes and adenylate cyclase activity. Cardiovasc Res 1985; 19: 693–9
   PubMedGoogle Scholar
• Schatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660–72
   Web of Science ®Google Scholar
• Stiles G L, Taylor S, Lefowitz R J. Human cardiac beta‐adrenergic receptors; subtype heterogenity delineated by direct radioligand binding. Life Sciences 1983; 33: 467–73
   PubMed Web of Science ®Google Scholar
• Cheng Y ‐C, Prusoff W H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–108
   PubMed Web of Science ®Google Scholar
• Minneman K P, Hedberg H, Molinoff P B. Comparison of beta adrenergic receptor subtypes in mammalian tissues. J Pharmacol Exp Ther 1979; 211: 502–8
   PubMed Web of Science ®Google Scholar
• Waelbroeck M, Taton G, Delhaye M, Chatelain P, Camus J C, Pochet R, Leclerc J L, De Smet J M, Robberecht P, Christophe J. The human heart beta‐adrenergic receptors. II. Coupling of beta‐adrenergic receptors with the adenylate cyclase system. Mol Pharmacol 1983; 24: 174–86
   PubMedGoogle Scholar
• Brodde O ‐E, Karad K, Zerkowski H ‐R, Rohm N, Reidemeister J C. Coexistence of β1 and β2‐ adrenoceptors in human right atrium. Direct identification by (±)‐[125I]‐iodocyano‐pindolol binding. Circ Res 1983; 53: 752–8
   PubMed Web of Science ®Google Scholar
• Robberecht P, Delhaye M, Taton G, De Neff P, Waelbroeck M, De Smet J M, Leclerc J L, Chatelain P, Christophe J. The human heart beta‐adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta1‐ and 50% beta2‐adrenergic receptors. Mol Pharmacol 1983; 24: 169–73
   PubMed Web of Science ®Google Scholar
• Åblad B, Borg K O, Carlsson E, Ek L, Johnson G, Malmfors T, Regardh C ‐G. A survey of the pharmacological properties of metoprolol in animals and man. Acta Pharmacol Toxicol 1975; 36(Suppl. V)7–23
   PubMedGoogle Scholar
• Lundgren B, Carlsson E, Herrman I. β‐ad‐renoceptor blockade by atenolol, metoprolol and propranolol in the anaesthetized cat. Europ J Pharmacol 1979; 55: 263–8
   PubMedGoogle Scholar
• Rönn O, Graffner C, Johnson G, Jordo L, Lundborg P, Wikstrand J. Haemodynamic effects and pharmacokinetics of a new selective beta1‐adrenoceptor agonist, prenalterol, and its interaction with metoprolol in man. Europ J Clin Pharmacol 1979; 15: 9–13
   PubMedGoogle Scholar
• Jennings G, Bobik A, Oddie C, Hargreaves M, Korner P. Cardioselectivity of prenalterol and isoproterenol. Clin Pharmacol Ther 1983; 34: 749–57
   PubMedGoogle Scholar
• Rohn N, Wagner J, Schumann H J. The lack of a pronounced preference of prenalterol for the beta‐1 adrenoceptor subtype. Naunyn‐Schmiedebergs Arch Pharmacol 1980; 315: 85–8
   PubMedGoogle Scholar
• Hedberg A, Mattsson H. Beta adrenoceptor interaction of full and partial agonists in the cat heart and soleus muscle. J Pharmacol Exp Therap 1981; 219: 798–808
   PubMedGoogle Scholar
• Ahlquist R P. Adrenergic beta‐blocking agents. Prog Drug Res 1976; 20: 27–42
   PubMedGoogle Scholar
• Wallin C ‐J, Hulting J. Massive metoprolol poisoning treated with prenalterol. Acta Med Scand 1983; 214: 253–5
   PubMed Web of Science ®Google Scholar
• Hedberg A, Carlsson E, Fellenius E, Lundgren B. Cardiostimulatory effects of prenalterol, a beta‐1 adrenoceptor partial agonist, in vivo and in vitro. Naunyn‐Schiedebergs Arch Pharmacol 1982; 318: 185–91
   PubMedGoogle Scholar
• Kaumann A J. On spare β‐adrenoceptors for inotropic effects of catecholamines in kitten ventricle. Naunyn‐Schmiedebergs Arch Pharmacol 1978; 305: 97–102
   PubMed Web of Science ®Google Scholar
• Venter J C. High efficiency coupling between beta‐adrenergic receptors and cardiac contratility. Direct evidence for ‘spare’ beta‐adrenergic receptors. Mol Pharmacol 1979; 16: 429–40
   PubMedGoogle Scholar
• Bristow M R, Ginsburg R, Minobe W, Cubicotti R S, Scott Sageman W, Lurie K, Billingham M E, Harrison D C, Stinson E B. Decreased catecholamine sensitivity and beta‐adrenergic‐receptor density in failing human hearts. N Engl J Med 1982; 307: 205–11
   PubMed Web of Science ®Google Scholar
• Bristow M R, Ginsburg R, Minobe W A, Harrison D C, Reitz B A, Stinson E B. β‐adrenergic receptor measurements in normal and failing human right and left ventricle. Circulation 1982; 66(Suppl. II)207
   Google Scholar
• Ginsburg R, Bristow M R, Billingham M E, Stinson E B, Schroeder J S, Harrison D C. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J 1983; 106: 534–40
   Google Scholar
• Bristow M R. Myocardial (3‐adrenergic receptor downregulation in heart failure. Intern J Cardiol 1984; 5: 648–52
   PubMed Web of Science ®Google Scholar
• Fowler M B, Bristow M R, Hopkins D G, Laser J A, Ginsburg R, Alderman E L, Schroeder J S. Impaired beta‐adrenergic inotropic response in severe heart failure. Circulation 1984; 70(Suppl. II)191
   Google Scholar